gene therapy

ATMPs News

In the lead up to the imminent FDA opinion on the biologics license application (BLA) for Novartis' gene therapy Zolgensma for the treatment of spinal muscular atrophy (SMA), the financial media company and magazine Forbes has published an interesting editorial on the controversial issues surround the pricing and reimbursement for ATMPs.

In the lead up to the imminent FDA opinion on the biologics license application (BLA) for Novartis' gene therapy Zolgensma for the treatment of spinal muscular atrophy (SMA), the financial media company and magazine Forbes has published an interesting editorial on the controversial issues surround the pricing and reimbursement for ATMPs.
April 29, 2019

In the lead up to the imminent FDA opinion on the biologics license application (BLA) for Novartis’ gene therapy Zolgensma for the treatment of spinal muscular atrophy (SMA), the financial media company and magazine Forbes has published an interesting editorial on the controversial issues surround the pricing and reimbursement for ATMPs.

The article includes an opinion on the potential issues surrounding the price for Zolgensma given the possible extended benefits from treating young paediatric patients, the severity of the condition and the relative price of the standard of care over the life time of patients, making it a new pricing paradigm compared to already approved ATMPs.

Search News & Events

  • Filter by category

Share

Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting